Hüser et al., 2018 - Google Patents
Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluationHüser et al., 2018
View HTML- Document ID
- 3738608328838947796
- Author
- Hüser S
- Guth S
- Joost H
- Soukup S
- Köhrle J
- Kreienbrock L
- Diel P
- Lachenmeier D
- Eisenbrand G
- Vollmer G
- Nöthlings U
- Marko D
- Mally A
- Grune T
- Lehmann L
- Steinberg P
- Kulling S
- Publication year
- Publication venue
- Archives of toxicology
External Links
Snippet
Isoflavones are secondary plant constituents of certain foods and feeds such as soy, linseeds, and red clover. Furthermore, isoflavone-containing preparations are marketed as food supplements and so-called dietary food for special medical purposes to alleviate health …
- 229930012948 isoflavones 0 title abstract description 301
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hüser et al. | Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation | |
Zhong et al. | Association between dietary isoflavones in soy and legumes and endometrial cancer: a systematic review and meta-analysis | |
Zhao et al. | Dietary isoflavones or isoflavone-rich food intake and breast cancer risk: A meta-analysis of prospective cohort studies | |
Touillaud et al. | Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status | |
Duffy et al. | Implications of phytoestrogen intake for breast cancer | |
Hamilton-Reeves et al. | Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-β expression or serum hormonal profiles in men at high risk of prostate cancer | |
Habito et al. | Effects of replacing meat with soyabean in the diet on sex hormone concentrations in healthy adult males | |
EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) | Risk assessment for peri‐and post‐menopausal women taking food supplements containing isolated isoflavones | |
Pietinen et al. | Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland | |
Holmes et al. | Does diet affect breast cancer risk? | |
Velentzis et al. | Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know | |
Messina et al. | Perspectives on the soy–breast cancer relation | |
Maskarinec et al. | A randomized isoflavone intervention among premenopausal women | |
Klein et al. | Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions | |
Lof et al. | Epidemiologic evidence suggests that dietary phytoestrogen intake is associated with reduced risk of breast, endometrial, and prostate cancers | |
Barlas et al. | The estrogenic effects of apigenin, phloretin and myricetin based on uterotrophic assay in immature Wistar albino rats | |
Budhathoki et al. | Soy food and isoflavone intake and endometrial cancer risk: the J apan Public Health Center‐based prospective study | |
Wang et al. | Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study | |
Valentín-Blasini et al. | Urinary phytoestrogen concentrations in the US population (1999–2000) | |
Woo et al. | Sex-specific associations of habitual intake of soy protein and isoflavones with risk of type 2 diabetes | |
Mishra et al. | Phytoestrogens and breast cancer prevention: what is the evidence? | |
Silva et al. | Phyto-oestrogen intake and breast cancer risk in South Asian women in England: findings from a population-based case-control study | |
Esch et al. | Isoflavones: toxicological aspects and efficacy | |
Mumford et al. | Urinary phytoestrogen concentrations are not associated with incident endometriosis in premenopausal women | |
Tomar et al. | Early life and adult exposure to isoflavones and breast cancer risk |